Armed with $125M, Nested Therapeutics debuts with plan to jumpstart next-gen precision oncology efforts
A new spinout emerged from stealth Thursday morning, backed by big name VCs and Big Pharma veterans at the helm to try to break into a new aspect of precision oncology medicine.
The biotech, Nested Therapeutics, is run by two former Genentech veterans who came to the startup after stints at Blueprint Medicines and Agios, leading a company that includes former Merck drug hunter Yongxin Han, who will head Nested’s drug discovery efforts. Other Nested co-founders include Kevan Shokat, the scientist whose team published the groundbreaking paper in 2013 detailing how KRAS, once thought undruggable, could be targeted. That paper ultimately paved the way for Amgen’s Lumakras, which got FDA approval last year for lung cancer with the mutation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.